In the past 16 months, Chinese biotechnology companies have emerged as significant players in the global pharmaceutical landscape. They have participated in approximately 6 out of 26 major licensing and acquisition deals, representing nearly one-third of the total value, which amounts to an impressive $53 billion. Notably, around half of these agreements involve American firms, primarily through mergers and acquisitions, while nearly 30% pertain to licensing deals with Chinese companies. The remaining deals include collaborations with European firms, showcasing a diverse and growing international presence.
Key Deals Highlighted
In December 2024, Merck made headlines by licensing an oral obesity treatment, HS-10535, from Hansoh Pharma, a company based in Jiangsu Province, China. This deal is valued at up to $2 billion. Following this, in March 2025, Merck again sought out Chinese innovation, this time licensing the heart drug HRS-5346 from Hengrui, also for a deal worth up to $2 billion.
The trend of acquiring Chinese biopharmaceutical assets continued into 2025. In July, Pfizer licensed the cancer candidate SSGJ-707 from 3SBio, with an upfront payment of $1.25 billion and potential milestone payments reaching $4.8 billion. Additionally, AstraZeneca secured a significant AI-led research pact with CSPC, a company based in Hebei Province, valued at up to $5.3 billion.
Continued Growth in 2026
As 2026 unfolded, AbbVie announced a licensing agreement for RemeGen’s RC148, targeted at advanced solid tumors, with a total deal value of up to $5.6 billion. Shortly thereafter, AstraZeneca returned to CSPC for another deal focused on obesity and weight-related drug candidates, which could amount to $18.5 billion, including $1.2 billion upfront.
In early March, Sanofi licensed rovadicitinib from the Chia Tai Tianqing unit of Sino Biopharm for up to $1.53 billion. By the end of March, Lilly expanded its collaboration with Insilico Medicine, a company headquartered in Cambridge, Massachusetts, and listed in Hong Kong, into a licensing and research agreement valued at up to $2.75 billion.
China’s Growing Influence in Pharma
Data from Citeline’s Pharmaprojects database indicates that more new drugs were launched in China than in any other country in 2025, marking a significant milestone as China surpassed the U.S. in this area for the first time. Fangning Zhang, a McKinsey partner, highlighted China’s unique combination of next-generation modality leadership and rapid, cost-effective R&D processes. He described Asia as the “emerging epicenter” of biopharma, suggesting a shift in global industry dynamics.
Future Predictions
Anticipating continued momentum, Tom Barsha, head of Asia Pacific M&A at BofA Securities, predicts that the total value of licensing deals originating from China could double in the next 18 to 24 months. This projection underscores the country’s burgeoning role in the biopharmaceutical sector.
Industry Knowledge and Expertise
Brian, the pharmaceutical and biotech editor at WTWH Media, brings nearly two decades of experience in B2B media, with a focus on healthcare and technology. His expertise extends to clinical trials, medical devices, and drug discovery, making him well-acquainted with the trends shaping the industry. His background includes significant roles in content direction and in-depth coverage of various life science topics.
Conclusion
The surge of Chinese biopharma firms in major pharmaceutical deals signals a seismic shift in the industry. As these companies continue to innovate and collaborate on a global scale, they not only enhance their market presence but also contribute to the advancement of drug discovery and development worldwide. The future looks bright for Chinese firms, with expectations for remarkable growth and influence in the coming years.
- Key Takeaways:
- Chinese firms accounted for 6 out of 26 major pharma deals in 16 months.
- The total value of these deals reached $53 billion.
- China surpassed the U.S. in new drug launches for the first time in 2025.
- Projections indicate that the value of licensing deals from China could double soon.
- Chinese biopharma is gaining recognition as a global innovation leader.
Read more → www.drugdiscoverytrends.com